Insider buying
~$1K2,500 sh @ $0.41
9 days before an 8-KTraded Dec 15, 2025 · filed 1 day later
The CEO of Silo Pharma paid $1K out of pocket for Silo Pharma shares.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Dec 15, 2025 · Filed Dec 16, 2025
The CEO of Silo Pharma paid $1.1K out of pocket for Silo Pharma shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$1,050
Shares × reported transaction price
<$25K
+1.2%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 1 month
Confirmed open-market purchases by the same insider in the available history
No
Compared with 4 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2024 ($630K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-06-30. The proxy does not tag the CEO's name, so the match rests on the Form 4 title only. A size comparison, not a judgement
Closed at $6.04 on Dec 15, 2025, 11% above its 52-week low and 80% below its high, after a 26% drop over the previous 30 trading days
52-week range $5.45 (Nov 20, 2025) to $29.70 (Jan 16, 2025), 2% of the way up, from 250 adjusted closes. 30 trading days earlier: $8.12 on Oct 31, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded 9 days before SILO filed an 8-K: received a notice from its stock exchange (Dec 24, 2025)
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.9% | +2.8% | −6.8% |
| 30 days | −5.8% | +3.0% | −8.8% |
| 90 days | −18.9% | −0.1% | −18.9% |
| 180 days | +5.2% | +12.4% | −7.2% |
Past results only. Not a forecast.
Insider buying
9 days before an 8-KTraded Dec 15, 2025 · filed 1 day later
The CEO of Silo Pharma paid $1K out of pocket for Silo Pharma shares.
Insider buying
Traded Nov 20, 2025 · filed 1 day later
The CEO of Silo Pharma paid $370 out of pocket for Silo Pharma shares.
Insider buying
Traded Nov 21, 2025 · filed the same day
The CEO of Silo Pharma paid $365 out of pocket for Silo Pharma shares.
Eric Weisblum, Chief Executive Officer's past purchases, 90 days after disclosure: 6 buys, median +3.6 pts vs S&P 500, beat it 3 of 6 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.